Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shingrix in adults ≥ 65 with/without prior Zostavax
NCT02581410Phase 3Completed
- Sponsor
- GSK
- Start
- Dec 2015
- Primary completion
- Aug 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of herpes zoster vaccine (recombinant, adjuvanted) in herpes zoster (HZ) (2 arms), sponsored by GSK. Primary endpoints: Anti-glycoprotein E Antibody Concentrations at Month 3, Number of Subjects With Solicited Local Symptoms and 4 more. Started Dec 2015; status: completed.
02
Drugs
herpes zoster vaccine (recombinant, adjuvanted)
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT02581410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02581410.